Final overall survival analysis of a phase II trial evaluating vinorelbine and lapatinib in women with ErbB2 overexpressing metastatic breast cancer  by Janni, Wolfgang et al.
lable at ScienceDirect
The Breast 24 (2015) 769e773Contents lists avaiThe Breast
journal homepage: www.elsevier .com/brstFinal overall survival analysis of a phase II trial evaluating vinorelbine
and lapatinib in women with ErbB2 overexpressing metastatic breast
cancer
Wolfgang Janni a, *, Tomasz Sarosiek b, Boguslawa Karaszewska c, Joanna Pikiel d,
Elzbieta Staroslawska e, Piotr Potemski f, Christoph Salat g, Etienne Brain h,
Christian Caglevic i, Kathryn Briggs j, 1, Kim Mahood j, 1, Michelle DeSilvio k, 1,
Luca Marini j, 1, Christos Papadimitriou l
a Universit€atsklinikum Ulm, Prittwitzstr 43, 89075 Ulm, Germany
b NZOZ Magodent, Fieldorfa 40, 04-0125 Warsaw, Poland
c Przychodnia Lekarska NZOZ KOMED, Ul Wojska Polskiego 6, 62-500 Konin, Poland
d Wojewodzkie Centrum Onkologii, Aleja Zwycie˛stwa 31, 80-219 Gdansk, Poland
e Centrum Onkologii Ziemi Lubelskieij, Doktor Kazimierza Jaczewskiego 7, 20-090 Lublin, Poland
f Uniwersytet Medyczny w Łodzi, Wojewodzki Szpital Specjalistyczny im. M.Kopernika, Pabianicka 62, 93-513 Lodz, Poland
g H€amato-Onkologische Gemeinschaftspraxis, Franz-Schrank-Str 2, 80638 Munich, Germany
h Ho^pital Rene Huguenin/Institut Curie, 35 Rue Dailly, Saint Cloud 92210, France
i Fundacion Arturo Lopez Perez, Rancagua 878, Providencia, Santiago 7500921 Chile
j Novartis Pharma AG, Basel, Switzerland
k Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
l Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, V.Sophias 80, 11528 Athens, Greecea r t i c l e i n f o
Article history:
Received 8 April 2015
Received in revised form
30 June 2015
Accepted 21 August 2015
Available online 16 September 2015
Keywords:
Breast cancer
HER2
Lapatinib
Vinorelbine
Capecitabine
Overall survival* Corresponding author. Department Obstetrics & G
500 58 502.
E-mail address: wolfgang.janni@uniklinik-ulm.de
1 Kathryn Briggs, Kim Mahood, Michelle DeSilvio, L
http://dx.doi.org/10.1016/j.breast.2015.08.005
0960-9776/© 2015 The Authors. Published by Elseviera b s t r a c t
Lapatinib plus capecitabine (lapþcap) is approved as treatment for patients with human epidermal
growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), who have progressed on prior
trastuzumab in the metastatic setting.
We previously reported progression-free survival (PFS), overall survival (OS) and safety results from
this open-label, multicentre, phase II study (VITAL; NCT01013740) conducted in women with HER2
positive MBC, to evaluate the efﬁcacy and safety of lap plus vinorelbine (lapþvin), an important
chemotherapy option for MBC, compared with lapþcap. In total, 112 patients were randomised 2:1 to
treatment with lapþvin (N ¼ 75) or lapþcap (N ¼ 37). Results showed that the median PFS (primary
endpoint) and OS (secondary endpoint) post-randomisation were comparable between treatment arms,
with no new safety signals detected.
Here, we assessed the ﬁnal OS in this study at 40 months post-randomisation. At the time of ﬁnal
analyses, 24 (32%) patients were ongoing in the lapþvin arm, compared with 14 (38%) patients in the
lapþcap arm (92% in both arms had discontinued treatment). Median OS in the lapþvin arm was 23.3
months (95% conﬁdence intervals [CI]: 18.5, 31.1), compared with 20.3 months (95% CI: 16.4, 31.8) in the
lapþcap arm. The median follow-up in the lapþvin arm was 18.86 months (95% CI: 10.68, 26.02),
compared with 19.38 (95% CI: 25.56) months in the lapþcap arm. Similar rates of death (56e57%) were
observed in both arms.
The ﬁnal OS was consistent with the previously reported data and suggest that lapþvin offers an
effective treatment option for women with HER2-positive MBC.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ynecology, Universit€atsklinikum Ulm, Prittwitzstr. 43, D-89075 Ulm, Germany. Tel.: þ49 731 500 58 500; fax: þ49 731
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therapy with trastuzumabwas permitted but not required. PatientsHuman epidermal growth factor receptor 2 (HER2)-positive
breast cancers are associated with aggressive disease and poor
prognosis, leading to shorter overall survival (OS) and disease-free
survival intervals [1], if not adequately addressed by targeted
treatment. Adequate HER2-targeted treatment may lead to similar
or even better survival compared with patients that have HER2-
negative breast cancer [2]. However, despite the considerable im-
provements in survival, patients with HER2-positive advanced/
metastatic breast cancer (MBC) will usually suffer from progressive
disease within 6e12 months of the initiation of a treatment line,
necessitating subsequent treatment options [3]. Multiple treatment
options, combining HER2-targeted agents and chemotherapy have
therefore been studied beyond the spectrum of the combinations
studied in the original registration trials. Particularly in patients
with progressive disease following treatment with trastuzumab,
lapatinib (lap)-containing regimens are an essential segment of the
spectrum of subsequent treatment options [4,5].
We previously reported ﬁndings from the ﬁrst prospective,
randomised study (VITAL; Clintrials.gov NCT01013740 (http://
clinicaltrials.gov/show/NCT01013740), GSK protocol number
LAP112620) of lapatinib and vinorelbine (lapþvin) in women with
HER2-positive MBC, which demonstrated comparable efﬁcacy with
lap plus capecitabine (lapþcap) [6]. Progression-free survival (PFS)
and overall survival (OS) data were observed in-line with data from
other studies of lapþcap [6]. Similar tolerability was also observed
between treatment arms and adverse events (AEs) were consistent
with the known lap, vin and cap safety proﬁles [6]. Herewe present
an update with mature OS data from the VITAL study for up to 40
months after randomisation.
Patients and methods
The study design, eligibility criteria, treatment plan, and
statistical analyses have been detailed in full in a prior publication
but are summarised here [6].
Study design
In this randomised, open-label, multicentre, phase II study,
patients were enrolled between November 2009 and February
2012 from 40 sites in 10 countries, and randomised (2:1) to lap
1250 mg orally once-daily (QD) continuously plus vin 20 mg/m2/
day intravenously on Day 1 and Day 8 every third week, or lap
1250mg orally QD continuously plus cap 2000mg/m2/day orally, in
2 doses 12 h apart on Days 1e14 every third week. Following dis-
ease progression on the randomised treatment, patients were given
the option of crossing over to the alternative treatment arm and
continuing in a post-progression crossover phase; all data con-
cerning these patients was reported previously [6]. Patients were
stratiﬁed by prior receipt of therapy for MBC (yes or no) and site of
metastatic disease (visceral/soft tissue or bone only). Random-
isation was centre based and performed using the interactive voice
response system [6]. The study was conducted in accordance with
Good Clinical Practice guidelines and the Declaration of Helsinki
and approved by local ethics committees.
Patient population
The study enrolled women 18 years of age with histologically
or cytologically conﬁrmed HER2-positive, stage IV breast cancer,
who had received no more than one prior chemotherapy regimen
(including anthracyclines and taxanes) in the metastatic setting.who had not received prior treatment for MBC were required to
fulﬁl certain criteria, as determined by the study investigator [6]. All
enrolled patients provided written informed consent.
Study assessments
Efﬁcacy
Tumour response data were assessed by the investigator
according to the Response Evaluation Criteria in Solid Tumours
(RECIST) guidelines [7].
The primary efﬁcacy endpoint was PFS (the time from ran-
domisation to the time of ﬁrst documented disease progression at
any site, or death due to any cause), assessed when all patients had
been followed-up for a minimum of 6 months and reported else-
where [6]. The principal secondary endpoint was OS (deﬁned as the
time from randomisation until death due to any cause), analysed at
the same point as PFS [6]. The updated OS analysis reported here
was planned for after all patients had a minimum of 18 months
follow-up; OS analyses were continued up to Month 40.
Safety
Toxicities were measured by recording the incidence and
grading of AEs and serious AEs (SAEs) during study treatment [6].
Treatment discontinuation and reasons for discontinuation were
monitored up to Month 40 in the safety population.
Statistical analysis
This report provides updated OS analyses of all women in the
intent-to-treat (ITT) population, which comprised all patients who
were randomised to study treatment, regardless of whether they
actually received study medication or not. All efﬁcacy analyses re-
ported were performed using SAS version 9.1. Clinical safety and
tolerabilitywere assessed in the safety population,which comprised
all patients who took at least one dose of study medication.
The control arm of lapþcap was included in the study design to
validate the patient population and to lend support to the activity of
lapþvin (the study was not formally powered to make a comparison
between treatmentarms).OSwas summarisedusing aKaplaneMeier
survival curve, from which the median OS (months) and 95% conﬁ-
dence intervals (CI) were calculated. The hazard ratio (HR) was
calculated based on the stratiﬁed log-rank test (the Pike estimator)
[8]. Greenwood's formula was used to calculate the standard error of
the estimates from the KaplaneMeier survival curve.
Results
Study population
The cut-off date for data collection, based on mature OS data,
was 3 October, 2013. In the VITAL study, a total of 112 eligible
patients were enrolled; 75 were randomised to lapþvin and 37
were randomised to lapþcap. Of these patients, 38 (51%) and 15
(41%) in the lapþvin and lapþcap arms, respectively, had received
prior trastuzumab in the (neo)adjuvant setting; 32 (43%) and 20
(54%) patients, respectively, had received trastuzumab in the
metastatic setting. At the time of ongoing analyses, 24 (32%)
patients were ongoing in the lapþvin arm, compared with 14 (38%)
in the lapþcap arm; and 9 (12%) patients had withdrawn in the
lapþvin arm, compared with 2 (5%) patients in the lapþcap arm (of
these, 4 [5%] patients withdrew consent in the lapþvin arm; none
withdrew consent in the lapþcap arm). Updated subject disposition
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reported previously [6]).
Final OS results
At completion, the median OS in the lapþvin arm was 23.3
months (95% CI: 18.5, 31.1 months), compared with 20.3 months in
the lapþcap arm (95% CI: 16.4, 34.8 months; HR [95% CI]: 0.99 [0.59,
1.67]) (Fig. 1). The median follow-up time was 18.9 months (range:
0.7, 42.8 months) in the lapþvin arm and 19.4 months (range: 1.8,
39.9 months) in the lapþcap arm. Proportionally, the numbers
of deaths were similar between treatment arms; 42 deaths (56%
patients) were recorded in the lapþvin arm compared with 21
deaths (57% patients) in the lapþcap arm (Table 1A; Fig. 1).
Safety and toxicity
At the time of ﬁnal analyses, 92% of patients in each arm had
discontinued treatment (Table 1B). The most common reasons for
discontinuation were disease progression, AEs and decision by
subject or proxy. In the previously reported analysis, AEs were
shown to be consistent with the known lap, vin, and cap safety
proﬁles and no new relevant safety signals were detected since that
analysis [6]. In the previous report the most commonly reported
AEs were diarrhoea, neutropenia, palmar-plantar eryth-
rodysesthesia, rash, nausea and fatigue; a larger proportion of
patients in the lapþcap arm experienced palmar-plantar eryth-
rodysesthesia and neutropenia occurred in a larger proportion of
patients treated with lapþvin. Of the neutropenia cases observed
with lapþvin, 10 AEs (13%) were extended to SAEs and were
considered related to study treatment [6]. In the randomised phase,
cardiac AEswere observed in 2 (3%) patients in the lapþvin arm and
4 (11%) patients in the lapþcap arm. No cardiac AEs were observed
in the crossover period.
Discussion
In this phase II, randomised study, which was the ﬁrst of its
kind, lapþvin demonstrated efﬁcacy comparable with lapþcap
[6]. The median PFS of 6.2 months in both treatment arms and
median OS of 24.3 months in the lapþvin arm and 19.4 months inTable 1
(A) Subject disposition (ITT population) and (B) Summary of study treatment discontinu
Lap 1250 mg QD plus vin 20 mg/m
A.
Completion status, n (%)
Completeda 42 (56)
Withdrawn 9 (12)
Ongoing 24 (32)
Primary reason for withdrawal, n (%)
Lost to follow-up 5 (7)
Withdrew consent 4 (5)
Investigator discretion 0
Study closed/terminated 0
B.
Status
Ongoing 6 (8)
Discontinued 69 (92)
Reason for discontinuation, n (%)
Disease progression 44 (59)
Adverse event 12 (16)
Decision by subject or proxy 6 (8)
Investigator discretion 5 (7)
Protocol deviation 2 (3)
Cap, capecitabine; ITT, intent-to-treat; lap, lapatinib QD, once daily; vin, vinorelbine.
a Completed is deﬁned as subjects who died.the lapþcap arm (all reported previously) were well matched with
those reported in other studies of lapþcap [5,9,10]. The data
support the potential use of lapþvin in the patients who have
progressed on ﬁrst-line treatment with trastuzumab (although it
should be noted that not all patients enrolled had prior trastu-
zumab treatment and it is unclear how changing treatment
affected OS in the patients who has previously progressed on
trastuzumab) [6]. As discussed below, pertuzumab in combination
with trastuzumab and docetaxel can be considered the standard
of treatment for ﬁrst-line therapy in patients with advanced
HER2-positive MBC, and the results of this study should therefore
be contextualised appropriately.
Overall, the updated, mature OS reported here (median of 23.3
months in the lapþvin, compared with a median of 20.3 months in
the lapþcap) are consistent with the ﬁrst analysis of OS and the
primary analysis of investigator-assessed PFS. However, it should
be noted that the study was not powered to detect signiﬁcant dif-
ferences in OS, which was reported descriptively; and although the
experimental armwas favoured by the 2:1 randomisation schedule,
limited conclusions can be drawn regarding the OS efﬁcacy data.
Moreover, any correlation between OS and PFS should be
interpreted with caution as patients in this study were given the
option of crossing over to the alternative treatment arm post-
progression [6]. Consistency between improvement in PFS and OS
has been reported in previous studies of trastuzumab in HER2-
positive MBC in the ﬁrst-line setting despite crossover [11,12];
however, we are not aware of any reports in further-line settings
such as this. OS is currently considered the most reliable endpoint
in studies evaluating cancer treatment, in which bias is not a factor
as it is based purely on the date of death and not the timing of the
tumour assessment. Although PFS is frequently used as an early
informative surrogate endpoint for OS, and reports of trial-level
treatment effect on PFS conﬁrm that it is signiﬁcantly associated
with the trial-level treatment effect on OS, the correlation between
the two is still uncertain in smaller, descriptive trials such as this
[13,14].
Since this study began, the treatment landscape for HER2-
positive MBC has altered rapidly. With the release of the
CLEOPATRA primary data and OS data [15,16], pertuzumab in
combination with trastuzumab is now fundamentally used in the
clinical setting as a ﬁrst-line treatment for metastatic HER2-ation (safety population).
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Fig. 1. KaplaneMeier plot: overall survival up to month 40 (ITT population). Cap, capecitabine; CI, conﬁdence intervals; HR, hazard ratio; ITT, intent-to-treat; lap, lapatinib; QD, once
daily; vin, vinorelbine.
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outcome seen in the CLEOPATRA trial led to accelerated US Food
and Drug Administration (FDA) approval for pertuzumab as ﬁrst-
line therapy in combination with trastuzumab and docetaxel for
advanced HER2-positiveMBC.While the patients whowere eligible
for the VITAL study were allowed to have received one line of
chemotherapy in the advanced or metastatic settings, 35% of the
enrolled patients received the study treatment as ﬁrst line within
these settings. In the context of the new dual-targeted treatment
standard comprising trastuzumab and pertuzumab, it is important
to mention that both studied treatment arms should not be
considered as ﬁrst-line treatment options, but as effective treat-
ment options for later-line treatment.
In the EMILIA clinical trial of women with advanced HER2-
positive MBC who had already been treated with trastuzumab
and a taxane, trastuzumab emtansine (T-DM1) signiﬁcantly
improved independently-assessed PFS (the primary endpoint), by
9.6 months compared with 6.4 months with the combination of
lapþcap (HR: 0.65; 95% CI: 0.55, 0.77; p < 0.001) [18]. Based on that
trial, the US FDA approved marketing of T-DM1 on 22 February,
2013. T-DM1 was approved speciﬁcally for treatment of HER2-
positive MBC in patients who have been treated previously with
trastuzumab and a taxane (paclitaxel or docetaxel), and who have
already been treated for MBC or developed tumour recurrence
within 6 months of adjuvant therapy. T-DM1 was also approved in
the EU in 2013, and is fast becoming the standard for second-line
treatment at progression [17] where it is approved. The recently
published TH3RESA study [19] evaluated the efﬁcacy and safety of
T-DM1 in comparison with treatment of the physician's choice in
patients with metastatic or unresectable locally advanced/recur-
rent HER2-positive breast cancer who have received at least two
prior regimens of HER2-directed therapy; all patients had been
pretreated with trastuzumab, a taxane, and lapatinib. This study
may therefore offer valuable insight into the placement of T-DM1 in
the treatment order. However, many unanswered questions still
remain regarding the order and optimal timing of treatment of
second- and further-line treatments. The European Society of
Medical Oncology clinical practice guidelines emphasise the
importance of continuing HER2 suppression for patients with
trastuzumab-exposed HER2 positive disease after progression [20];
in future, potentially viable options could therefore include a dual
HER2 blockade with T-DM1 in combination with another antibody
or with chemotherapy.
In addition to increasing treatment options for ﬁrst-line therapy,
provision of further treatment options as therapy in later lines isalso beneﬁcial as it allows a better choice for patients. The data
from this study suggest that where lap plus chemotherapy is
considered for patients with HER2-positive MBC, lapþvin offers an
effective treatment option, validated by the lapþcap control arm.Conclusions
Final, mature OS analysis in this study (VITAL; LAP112620;
NCT01013740) showed that OS remained comparable between
lapþvin and lapþcap inwomenwith HER2-positive MBC. Although
limited by the size of the study and descriptive nature of the efﬁ-
cacy results, these ﬁndings provide further evidence that lapþvin
offers an effective treatment option in the metastatic setting.Authorship contributions
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